Related by context. All words. (Click for frequent words.) 66 RNAi Therapeutic 66 Initiates Clinical 66 Prolongs Survival 66 HDL Selective Delipidation 66 Tumor Response 66 Biostatistical 66 Cytochrome P# 66 Immunotherapeutic 66 HCV Protease Inhibitor 66 Novel Small Molecule 66 Extracellular Matrix 66 preclinical efficacy 65 Initiates Clinical Trial 65 See CLINICAL PHARMACOLOGY 65 eTag assays 65 Novel Therapies 65 pharmacodynamic parameters 65 Molecular Diagnostic 65 Tyrosine Kinase Inhibitor 64 Nucleic Acids 64 Anticancer Agents 64 p# biomarker 64 Presents Preclinical Data 64 Reports Preclinical Data 64 Cethromycin 64 Novel Therapeutic 64 Genetic Screening 64 Hepatotoxicity 64 Lymphoid 64 Metabolic Disease 64 Adult Stem Cell Therapy 64 Clinical Outcome 64 Prognostic Value 64 Cardiotoxicity 64 Antiviral Activity 64 Phase 2b Clinical Trial 64 Drug Metabolism 64 Virologic 63 Novel Vaccine 63 Cytogenetic 63 Bioequivalence 63 Potent Inhibitor 63 Pharmacodynamic 63 Pharmacogenetic 63 Demonstrates Statistically Significant 63 Preclinical Models 63 Modulates 63 Anti Tumor 63 Diabetic Foot Ulcer 63 Antisense Drug 63 Protein Expression 63 Intravenous Immunoglobulin 63 Mutation Analysis 63 preclinical toxicology 63 Antibody Discovery 63 Phase IIb Clinical Trial 63 Protexia ® 63 Antitumor 63 HDAC Inhibitor 63 Hematological 63 Postdoctoral Position 63 Interferon Beta 63 Immunogenicity 63 Progenitor Cells 63 Potent Antiviral Activity 63 Small Molecule 62 fosbretabulin 62 Cardiomyocytes 62 Therapeutic Antibody 62 Renal Cancer 62 Estrogen Receptor 62 Gastrointestinal Stromal Tumors 62 Predictive Toxicology 62 CAMPATH 62 Kinase Inhibitors 62 Protein Interactions 62 cMET 62 Malignant Glioma 62 Thorough QT 62 Hematologic 62 rxRNA 62 Meets Primary Endpoint 62 Dr. Michelle Berrey 62 JAK2 Inhibitor 62 Factor VIIa 62 Proteasome 62 CCX# 62 Cytometry 62 Inflammatory Diseases 62 Novel Oral 62 BEXXAR Therapeutic Regimen 62 Drug Candidate 62 Therapeutic Antibodies 62 Successfully Completes Phase 62 Immunologic 62 Biocompatibility 62 Clinical Evaluation 62 Clinical Trial Data 62 PEG SN# 62 vitro pharmacology 62 EGFR HER2 62 Kinase Inhibitor 62 Dendritic Cells 62 Hematopoietic 62 ALN TTR 62 Pharmacogenomic 62 Human Antibody 62 Demonstrates Potent 62 Clinical Trial Results 62 GRNCM1 62 Fabry Disease 62 Parathyroid Hormone 62 Diabetic Neuropathy 62 Collaborators Present 62 clevidipine 61 Left Ventricular Dysfunction 61 Systemic Delivery 61 Phase 2b Trial 61 Progenitor Cell 61 microplasmin Phase III 61 Prodarsan R 61 OvaRex R 61 Investigational Treatment 61 uricase 61 RNAi Therapeutics 61 Maven Semantic 61 bFGF 61 Aurora Kinase 61 Antiangiogenic 61 Exosome 61 metabolite profiling 61 Respiratory Virus 61 Cardiometabolic 61 prostanoid 61 Inosine 61 Shows Efficacy 61 Pharmacokinetic 61 Preclinical Data 61 MGd 61 Investigational Drug 61 Bone Metastases 61 Antitumor Activity 61 ThermoDox ® clinical 61 Clinical Decision Making 61 Protexia R 61 Percutaneous Tibial Nerve Stimulation 61 Companion Diagnostics 61 Epithelium 61 #:#-# [033] 61 rhMBL 61 Universal Flu Vaccine 61 Interferon Gamma 61 BiTE Antibody 61 Patients Treated With 61 JAK Inhibitor 61 Initiate Clinical Trial 61 SUTENT ® 61 Preclinical Study 61 Faropenem 61 Cell Signaling 61 potent suppressor 61 ALISTA 61 Schizophrenia Treatment 61 Laryngeal Cancer 61 TB Vaccine 61 PSMA ADC 61 Flow Cytometry 61 Galectin 3 61 trastuzumab DM1 T DM1 61 Lupus Drug 61 Cancer Stem Cells 61 Biothreat 61 Diagnostic Criteria 61 Computed Tomographic 61 Proliferative 61 Xelox 61 Protein Biomarker 61 Molecular Genetic 61 abacavir Ziagen 61 Microdosing 61 Metabolic Endocrinology 61 Shows Promise Against 61 Embolic Protection 60 hematological parameters 60 Collaborators Publish 60 Onalta TM 60 immunotoxicity 60 Antigen CEA 60 Antithrombin 60 Hepatitis C Virus 60 CINtec R 60 hyaluronidase enzyme 60 vitro experiments 60 Ozarelix 60 C1 Inhibitor 60 Vaccine Protects Against 60 Cytotoxic 60 biostatistical analysis 60 Therapeutic Agents 60 Pyridorin TM 60 Phase Ib Clinical Trial 60 Anticancer Activity 60 Demonstrates Efficacy 60 Psoriasis Drug 60 Mimetics 60 HEPLISAV TM 60 HER2 overexpression 60 Combo Therapy 60 Anticancer Drug 60 #:#-# [035] 60 Immunodiagnostics 60 Preclinical 60 Hypercholesterolemia 60 Clinical 60 Lung Cancer Drug 60 Toxicogenomics 60 Serious Adverse Events 60 Protease Inhibitors 60 Arch Neurol 60 Regulatory Toxicology 60 ALN HPN 60 Investigator Initiated 60 Novel Antibiotic 60 Solid Tumor 60 Echocardiographic 60 Monoclonal Antibody 60 Presents Preclinical 60 DNA Microarray 60 Epithelial Cell 60 Tumor Microenvironment 60 Pandemic Influenza Vaccines 60 Acute Ischemic Stroke 60 vivo validation 60 Demonstrates Sustained 60 Bioartificial Liver 60 Biphasic 60 Histologic 60 Minimally Invasive Treatment 60 BioSante Pharmaceuticals Reports 60 Recombinant Human 60 RhuDex 60 Electroporation 60 Diagnostic Tests 60 Inflammatory Arthritis 60 Drug Formulation 60 Pulmonary Arterial Hypertension 60 preclinical pharmacokinetic 60 Transdermal Delivery 60 Liprotamase 60 Valortim ® 60 Refractory Angina 60 NOD mouse 60 Chronic Renal Failure 60 Adipose Derived Stem Cells 60 Randomized Double blind 60 Multiple Myeloma Patients 60 ChronVac C R 60 ONCONASE R 60 Biomarker Study 60 Immune Tolerance 60 OraTest R 60 Kahalalide F 60 CALGB # [002] 60 Confirms Efficacy 60 Drug Repositioning 60 Zemplar Capsules 60 Tyrosine Kinase Inhibitors 60 Oral Fingolimod 60 Urogenital 60 Fondaparinux 60 Completes Patient Enrollment 60 Pathology Microbiology 60 Novel Inhibitor 60 Reveals Significant 60 Recombinant Protein 60 Preclinical Studies 60 Tesmilifene 60 Shows Promising 60 Myelodysplastic Syndromes 60 hepatoma 60 Aliskiren 60 Secretase 60 DNA methyltransferases 60 Allogeneic 60 Decitabine 60 Personalized Oncology 60 Transfection 60 Technosphere ® 60 Quantitation 60 Achieves Primary Endpoint 60 Treating Chronic 60 Tissue Repair 60 Phase Ib II 60 pharmacodynamic markers 60 Pharmacoeconomic 60 Significant Improvements 60 Androxal TM 60 Medical Countermeasure 60 Hsp# Inhibitor 60 pharmacogenetic testing 60 Physiology Seminar 60 Bioavailability 60 Chemical Synthesis 59 Cervical Dysplasia 59 Neural Stem Cell 59 Phase IIA 59 PhG alpha 1 59 Receives Milestone Payment 59 Viral Infections 59 Nebulized 59 K ras mutations 59 GLP toxicology studies 59 Showed Significant 59 DXL# 59 Deforolimus 59 Hedgehog Pathway Inhibitor 59 riociguat 59 PBMCs 59 CEQ# 59 Atopic Dermatitis 59 Beta catenin pathway 59 #:#-#,# CrossRef Medline [002] 59 CALGB 59 Growth Hormone Deficiency 59 experimental allergic encephalomyelitis 59 mGluR2 NAM 59 differential gene expression 59 Civacir 59 Oral Insulin 59 Patients Receiving 59 Anti Tumor Activity 59 preclinical pharmacology 59 Crit Rev 59 Inovio DNA 59 CIMZIA ™ 59 Severe Asthma 59 Assay Kits 59 Pivotal Phase II 59 Amplicor 59 Circulating Tumor Cells 59 metastatic neuroendocrine tumors 59 Myocardial Perfusion Imaging 59 Cell Transplant 59 Adverse Event 59 Advanced Melanoma 59 Cellular Immunology 59 Tumor Suppressor Gene 59 Renal Cell Cancer 59 THR beta agonist 59 immunotherapeutic vaccine 59 Phase III Pivotal 59 Mouse Models 59 B2A 59 Onconase 59 Anti Infective 59 Synthetic Peptide 59 Long Term Efficacy 59 Recombinant Proteins 59 vitro ADME 59 Antigen Specific 59 Therapeutic Potential 59 acetonide FA 59 deCODE chemistry 59 Bloodstream Infections 59 Vidofludimus 59 CINTREDEKIN BESUDOTOX 59 chronic eosinophilic leukemia 59 Diastolic Heart Failure 59 Wellstat 59 Cannabinoid 59 rhFVIIa 59 Peripheral Arterial 59 Smooth Muscle 59 Solid Tumors 59 Immunomedics Announces 59 Vaccine Candidate 59 Phase IIIB IV 59 Tumor Angiogenesis 59 AEGR 59 Humate P 59 FDA CDER 59 azilsartan medoxomil 59 Thrombotic 59 Mutagenesis 59 Bacteremia 59 Vicriviroc 59 rFactor XIII 59 Severe Sepsis 59 PROSTASCINT R 59 Genotypic 59 BUPHENYL R 59 Gastrointestinal Disorders 59 Inhibitory 59 CD# CEA 59 Infinium assay 59 BAL# [002] 59 Structure Function 59 Susceptibility Testing 59 Renal Insufficiency 59 WRAIR 59 masitinib 59 Catheter Associated 59 haematopoietic 59 BrachySil TM 59 Tigecycline 59 Monoclonal 59 Cellular Therapies 59 porcine derived 59 Tuberculosis Vaccine 59 Presents Positive Preclinical 59 Presents Positive 59 MEK Inhibitor 59 Autologous Stem Cell Transplantation 59 Microbial Genomics 59 midstage clinical 59 Teriflunomide 59 EDEMA3 trial 59 Receives Orphan Drug 59 Kidney Function 59 Neurobiological 59 Phase III Clinical Trial 59 Proellex TM 59 Sequencing Systems 59 Present Preclinical Data 59 Drug Shows Promise 59 Antiviral Therapy 59 relapsed MM 59 Glycosylation 59 THALOMID 59 Vascugel ® 59 adult mesenchymal stem 59 Analyte 59 Innate Immune 59 Milestone Payment 59 Drug Prevents 59 IND Application 59 #D#C# 59 Inflammatory Markers 59 AtherOx 59 vidofludimus 59 Metabolic Disorder 59 Granulocyte Colony Stimulating Factor 59 Anticancer Agent 59 Cell Differentiation 59 Xcytrin R 59 vivo preclinical 59 Pemphigus 59 epigenetic therapies 59 Immunohistochemistry 59 histone deacetylase inhibitor 59 Phase 2a Trial 59 MAGE A3 ASCI 59 Localized Prostate Cancer 59 Novel Mechanism 59 Nicotine Vaccine 59 ENMD # 59 Lung Injury 59 Female Urology 59 Iron Overload 59 Improves Outcomes 59 Pafuramidine 59 Rotavirus Vaccine 59 solithromycin 59 Nanoemulsion 59 Pharmacologic 59 Forodesine HCl 59 Intravenous Formulation 59 immunotoxins 59 butyrylcholinesterase 59 Tumor Targeting 59 Vaccine Immunology 59 Initiates Enrollment 59 Pancreatic Islet 59 transgenic rats 59 ORENCIA R 59 Immune Therapy 59 Chemotherapeutic Agents 59 Inactivation 59 immunoregulation 59 Epidermal Growth Factor Receptor 59 Epidemiological Studies Unit 59 Radiopharmaceutical 59 A3 adenosine receptor 59 Files IND 59 Pharmacokinetic PK 59 Demonstrates Ability 59 null responder 59 UPLYSO 59 kidney urologic 59 Multidrug Resistant 59 Gets FDA Clearance 59 #beta HSD1 58 Protease Inhibitor 58 VP# [004] 58 Prodarsan ® 58 Teriparatide 58 Enzyme Replacement Therapy 58 Meta analyzes 58 recurrent glioma 58 BioVant 58 Inhaled Nitric Oxide 58 Antifungal 58 Metastatic Renal Cell Carcinoma 58 platelet dysfunction 58 Demonstrates Positive 58 hMG 58 Demonstrates Significant 58 Interferon beta 58 Epitopes 58 Vancocin R 58 Septin9 58 Nonalcoholic Steatohepatitis 58 Lymphocytic 58 Sunesis Pharma 58 Gastric Cancer 58 Confirmatory 58 adipose derived stem cells 58 Preclinical Efficacy 58 Calcitonin 58 NDA Submission 58 Portal Hypertension 58 Avian Flu Vaccine 58 Serological 58 HCV polymerase 58 Seasonal Influenza Vaccine 58 Develops Novel 58 Antibody Drug Conjugate 58 Vaccine Adjuvant 58 Glybera R 58 STRIDE PD 58 Preclinical Development 58 SmartChip TM Real 58 Patient Oriented 58 thalidomide Thalomid 58 Telik Announces 58 Stem Cell Transplants 58 Tumor Cell 58 CHAMPION PCI 58 microRNA profiling 58 Genes Involved 58 Heterogeneity 58 pharmacogenomic translational research 58 Lymphocyte 58 Prospective Randomized 58 Biophysical 58 Romidepsin 58 Combination Treatment 58 Cardioprotection 58 Improve Diagnosis 58 Cystatin C 58 Evoltra ® 58 mechanistic studies 58 p# inhibitor 58 transcranial Doppler ultrasound 58 Radiation Induced 58 TPMT 58 Translational Biology 58 ADAGIO study 58 Ventricular Arrhythmias 58 PK PD 58 Hematological Cancers 58 Anavex #-# 58 #:#-# [003] 58 Hematologic Malignancies 58 depsipeptide 58 Skeletal Muscle 58 SNP Genotyping 58 Gamunex C 58 Placental 58 Phase IIa Clinical Trial 58 Lp PLA 2 58 stated Michelle Berrey 58 Liver Function 58 Oncologic 58 Late Breaker 58 FS Antihemophilic Factor Recombinant 58 PRECISE trial 58 Demonstrate Significant 58 MGN# 58 Urology Gynecology 58 Biomarker Discovery 58 lexidronam injection 58 Hormone Receptor Positive 58 Exherin TM 58 Inhaled Liposomal Ciprofloxacin 58 Pivotal Phase III 58 NAVISTAR R 58 Dalbavancin 58 Haptoglobin 58 P#Y# [001] 58 Companion Diagnostic 58 phosphorylated tau 58 gefitinib Iressa 58 Ecallantide 58 cytogenic 58 busulfan 58 Systemic Sclerosis 58 Meta Analysis 58 XYOTAX TM 58 Fungal Infections 58 Vertebral Fracture 58 Secondary Hyperparathyroidism 58 Biochemistry Microbiology 58 chimeric antibody 58 TKM ApoB 58 Coronary CTA 58 myelodysplastic myeloproliferative diseases 58 INCB# [001] 58 Dehydrogenase 58 Breast Density 58 Statistical Methods 58 BARACLUDE R 58 clinical pharmacology studies 58 Reduces Mortality 58 TransVax ™ 58 Pharmacokinetic Study 58 Anticalin ® 58 Immutep 58 Plaque Psoriasis 58 Molecular Pathogenesis 58 ospemifene 58 Islet Transplantation 58 Translational Science Awards 58 forodesine 58 HCV Infection 58 Val HeFT 58 nucleic acid isolation 58 Hematopoietic Stem Cells 58 Activity Assay 58 Mouse Model 58 Files Investigational 58 Submits Response 58 R lenalidomide 58 Adjuvant Chemotherapy 58 Estradiol 58 Exelixis XL# 58 Significantly Improves 58 Immunoassay 58 Apoptotic 58 Sipuleucel T 58 AmpliChip 58 NEUGENE 58 alemtuzumab MS 58 Attenuated 58 Relapsing Multiple Sclerosis 58 TCGA Pilot Project 58 Myeloperoxidase 58 Prophylactic Treatment 58 Test Detects 58 randomizing patients 58 selective inhibition 58 ALK inhibitors 58 Investigational Compound 58 Neurodegenerative Disease 58 Significantly Improved 58 Randomized Evaluation 58 OvaRex MAb 58 Quantitative PCR 58 Clinical Validation 58 Mesenchymal Stem Cells 58 Exploratory IND 58 Neuroprotection 58 Autoimmune Disease 58 Cervical Cytology 58 pharmacodynamic PD 58 Novel Treatments 58 Neurotherapeutics 58 protein tyrosine phosphatase 1B 58 Chimigen TM 58 Microbial Identification 58 Azedra 58 Excretion 58 clonogenic 58 Panzem R 58 Cancer Vaccines 58 ALN PCS 58 PROSTVAC VF 58 tubulin inhibitor 58 GATTEX TM 58 Renal Function 58 epoetin alpha 58 NPM1 58 PDE# inhibitors 58 Renal Anemia 58 DMPK 58 Analytical Method 58 Ocrelizumab 58 Alkaline Phosphatase 58 TLR antagonists 58 sargramostim 58 FOR FURTHER INFORMATION ABOUT 58 Neuroanatomy 58 Monoclonal Antibodies 58 J Clin 58 sitaxsentan 58 Begin Clinical Trials 58 Multimeric 58 Elagolix 58 Golimumab 58 Leukemias 58 diarrhea predominant irritable 58 Comparative Genomic Hybridization 58 Antisoma AS# 58 Disease Modifying 58 CYT# potent vascular disrupting 58 Motility 58 Nuclear Receptor 58 subcutaneous immunoglobulin 58 Oral Insulin Capsule 58 ® C1 esterase 58 Ancrod 58 Velcade bortezomib 58 Signaling Pathway 58 Talactoferrin 58 Immunochemistry 58 mediated inhibition 58 Aeolus Pharmaceuticals Announces 58 Novel Compound 58 Ramoplanin 58 Gene Expression Analysis 58 Bucindolol 58 Daptomycin 58 LT NS# 58 aminotransferase 58 topically administered 58 Anticoagulant 58 Protein Function 58 Bioanalytical 58 Macrolide 58 Genetic Markers 58 antiangiogenic agents 58 Kinoid 58 Azacitidine 58 NS5A 58 PAREXEL Consulting 58 conducted retrospective cohort 57 MassGeneral Institute 57 Trofex 57 Secretory 57 Entereg R 57 Castration Resistant Prostate Cancer 57 Valortim TM 57 Mass Spectroscopy 57 Platelet Function 57 Psychiatric Epidemiology 57 Signaling Pathways 57 sunitinib Sutent 57 Eukaryotic 57 Polymorphisms 57 bazedoxifene conjugated estrogens 57 Randomized Clinical Trials 57 myeloperoxidase 57 MYCAMINE 57 PEGPH# 57 #:#-# [023] 57 Clinically Significant 57 ImmuKnow R 57 ANN INTERN MED 57 synDNA TM 57 Postmarketing 57 FDA Approvals 57 Hemostasis 57 RIGScan CR 57 Double Blind Randomized 57 Endovascular Treatment 57 Lenocta 57 #:#-#,# [003] 57 Iluvien TM 57 Inhalation Solution 57 Genomic Analysis 57 UGT#A# 57 Thrombin 57 Initiates Phase II 57 RECOTHROM R 57 KRAS mutation 57 Phase Ib clinical 57 Injectable Drug 57 Autologous Thrombin Processing 57 Myocardial Ischemia 57 Warfarin Coumadin 57 Transcription Factor 57 HIF 1a 57 Oxidized LDL 57 antineoplastic 57 Clinical Outcomes 57 R#/MEM # 57 OHRI 57 NIH SBIR 57 metabolite identification 57 SOLiD ™ 57 Pharmacodynamics 57 Nymox NX 57 BrachySil ™ 57 Patient Outcomes 57 Anti Angiogenic 57 Fibroblast 57 Dasatinib 57 Prof. Gozes 57 bronchial epithelial cells 57 multicenter clinical trials 57 Pharmacokinetics PK 57 Am J Geriatr 57 Neurodegenerative 57 rhLF 57 Immunostimulatory 57 Rheumatoid Arthritis Patients 57 Pivotal Study 57 JAK inhibitor 57 Protein Interaction 57 JAK3 57 Biochemical Genetics 57 inhaled treprostinil 57 Fibrillex TM 57 CIMZIA TM certolizumab pegol 57 Autoimmune Disorders 57 Hyperlipidemia 57 hepatic insufficiency 57 Aflibercept 57 Receives Orphan Drug Designation 57 Phase 2b Study 57 ZFN modified 57 Immunoglobulin 57 Contrast Enhanced 57 Novel Therapeutics 57 Monocytes 57 Zinc Finger 57 Virosome Biologicals 57 siRNAs targeting 57 Initiate Phase 57 Lixivaptan 57 PKC# 57 Zemiva TM 57 NGFN 57 Helicobacter Pylori 57 Erythropoietic 57 Oral Calcitonin 57 Somatostatin 57 Cytotoxicity 57 Transcriptome 57 IL# PE#QQR 57 Phase III Clinical Trials 57 Dose Escalation 57 Submits NDA 57 ANTEGREN 57 Taxane 57 Interferon Alfa 57 Completes Dosing 57 Genotyping 57 LibiGel ® 57 pDC 57 GRN# 57 Epratuzumab 57 myopathy rhabdomyolysis 57 MOVIPREP R 57 Therapeutic Vaccine 57 Triolex 57 bioscavenger 57 Stakeholder Opinions 57 Progressive Multifocal Leukoencephalopathy 57 Muscle Wasting 57 Epstein Barr Virus EBV 57 Left Ventricular 57 BIIR 57 Eculizumab 57 Population Genetics 57 Potent Anti 57 Pharmacother 57 antidiabetic drug 57 Bio Engineered 57 demonstrated antitumor activity 57 Clinical Efficacy 57 Commercialize Novel 57 Protein Synthesis 57 Chemoprevention 57 genetic polymorphism 57 Corgentin 57 Cell Signalling 57 genomic biomarker 57 Phenotypic 57 YONDELIS 57 Immunosuppressive 57 intracranial hemorrhage ICH 57 Services #:#-#,# Abstract 57 Haplotype 57 Aortic Valve 57 Multiple Ascending Dose 57 Known hypersensitivity 57 Stereotactic Radiosurgery 57 OHR/AVR# 57 Molecular Oncology 57 Serologic 57 Ebola Vaccine 57 Prostate Disease 57 PREGNANT Study 57 SPRYCEL ® 57 Theranostics 57 Phase #/#a trial 57 Clostridium difficile Infection 57 Peyronie Disease 57 Immune Cell 57 Breast Tumor 57 Teva Provides Update 57 Molecular Cancer 57 Pegylated 57 Benign Prostatic Hyperplasia 57 rPA Anthrax Vaccine 57 ADVIA 57 monoclonal antibody mAb 57 P#X# 57 Cancer Biomarkers 57 therapeutic regimens 57 Erythropoiesis Stimulating Agents 57 Ridaforolimus 57 eprotirome 57 Myoblast 57 Differential Diagnosis 57 MetaDrug TM 57 Taligen Therapeutics 57 NABTT 57 Oligonucleotides 57 Phase III Trial 57 miRview meso 57 LB# [003] 57 genotypic resistance 57 Tolerability Study 57 NSABP 57 Investigational Agent 57 Homeostasis 57 Vaxfectin R 57 Targeted Therapies 57 Heritability 57 Immune Mediated 57 Hepatocellular Carcinoma 57 ERYtech 57 Uric Acid 57 Immune Responses 57 Anticoagulation 57 Omacetaxine 57 Genetic Disease 57 Genetic Variation 57 adalimumab Humira 57 CRLX# 57 ImmunoCellular Therapeutics 57 Trandolapril 57 Uterine Cancer 57 Vaxfectin R formulated 57 Improved Survival 57 HuCAL GOLD R 57 PORxin TM platforms 57 Nipent R 57 Inhibin 57 Septin 9 57 Therapeutic Monoclonal Antibodies 57 baseline LDH 57 neuropsychiatric diseases 57 Alexion Soliris 57 Fibrinogen 57 CRMD# 57 Phosphorylation 57 Morpholino 57 acadesine 57 NurOwn 57 Biomarker 57 Genetic Testing 57 Cardiac Rhythm 57 Mucosal 57 virosome 57 cathepsin K inhibitor 57 plasmid DNA vaccine 57 Synaptic Plasticity 57 EHT AGN 57 Angiogenic 57 Molecular Basis 57 DNA Sequencer 57 Neoadjuvant Chemotherapy 57 Combination REOLYSIN R 57 ara C 57 #:#-#,# [002] 57 Renal Cell Carcinoma RCC 57 Degarelix 57 davunetide intranasal AL 57 HuMax 57 Osteoarthritis Patients 57 Study Evaluating 57 segment Biotest 57 favorable pharmacokinetic profile 57 Tß4 57 Azedra TM 57 monocytes macrophages 57 RAV# 57 Protein Therapeutics 57 Adjuvanted 57 Synta Announces 57 Molecular Mechanism 57 drugs davunetide intranasal 57 Androgen 57 MERLIN TIMI 57 Levels Linked 57 histone deacetylase HDAC